Endoscopic fluorescence detection of low and high grade dysplasia in Barrett's oesophagus using systemic or local 5-aminolaevulinic acid sensitisation

BACKGROUND AND AIMS Barrett's oesophagus is associated with an increased risk of cancer. As dysplasia is not visible during routine endoscopy, random biopsies in the four quadrants every 1-2 cm are recommended. Endoscopic fluorescence detection (EFD) after sensitisation with 5-aminolaevulinic acid (5-ALA) with different modes and concentrations was assessed to optimise the technique for detection of dysplasia or early cancers. 5-ALA is converted intracellularly to protoporphyrin IX which accumulates in malignant tissue and can be detected by typical red fluorescence after illumination with blue light. METHODS In 47 patients with Barrett's oesophagus, 10 with known dysplasia, 58 fluorescence endoscopies were performed after sensitisation with different concentrations of 5-ALA given orally (5, 10, 20, 30 mg/kg) or locally (500-1000 mg) by spraying the mucosa via a catheter. EFD was performed 4-6 hours after systemic and 1-2 hours after local sensitisation using a special light source delivering white or blue light. A total of 243 biopsies of red fluorescent (n=113) and non-fluorescent areas (n=130) were taken. RESULTS In three patients, two early cancers and dysplasia, not visible during routine endoscopy, were detected by EFD. Thirty three biopsies revealed either low or high grade dysplasia. Sensitivity for detection of dysplastic lesions ranged from 60% after local sensitisation with 500 mg to 80%, 100%, and 100% after systemic application of 5-ALA 10, 20, and 30 mg/kg, respectively. However, specificity was best for local sensitisation (70%) while systemic administration revealed values between 27% and 56%. Using 5 mg/kg, no red fluorescence in dysplastic lesions was found. No severe side effects were noted. CONCLUSION EFD is a promising tool to detect non-visible dysplastic lesions in Barrett's oesophagus using 5-ALA sensitisation. A randomised controlled study is now indicated to compare the efficacy of EFD with the standard technique of four quadrant random biopsies.

[1]  Patricia L. Blount,et al.  An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. , 1993, Gastroenterology.

[2]  R. Straight,et al.  Fluorescence localization of early colonic cancer in the rat by hematoporphyrin derivative , 1991, Lasers in surgery and medicine.

[3]  K. Lewin,et al.  Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. , 1992, Human pathology.

[4]  J. Goldblum,et al.  Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. , 1999, Gastrointestinal endoscopy.

[5]  R. Sampliner,et al.  The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. , 1997, The American journal of gastroenterology.

[6]  J. Schölmerich,et al.  Detection of dysplastic lesions by fluorescence in a model of colitis in rats after previous photosensitization with 5-aminolaevulinic acid. , 1998, Endoscopy.

[7]  P. Dítě,et al.  [Barrett's esophagus]. , 2000, Bratislavske lekarske listy.

[8]  R. Sampliner,et al.  Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus , 1998, American Journal of Gastroenterology.

[9]  Martin Kriegmair,et al.  CELLULAR FLUORESCENCE OF THE ENDOGENOUS PHOTOSENSITIZER PROTOPORPHYRIN IX FOLLOWING EXPOSURE TO 5‐AMINOLEVULINIC ACID , 1995, Photochemistry and photobiology.

[10]  K Svanberg,et al.  Clinical spectral characterisation of colonic mucosal lesions using autofluorescence and δ aminolevulinic acid sensitisation , 1999, Gut.

[11]  S. Re,et al.  The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. , 1997 .

[12]  J. G. van den Tweel,et al.  Barrett's esophagus: development of dysplasia and adenocarcinoma. , 1989, Gastroenterology.

[13]  J Moan,et al.  5‐Aminolevulinic acid‐based photodynamic therapy , 1997, Cancer.

[14]  D. V. von Rueden,et al.  Photo detection of carcinoma of the colon in a rat model: A pilot study , 1993, Journal of surgical oncology.

[15]  B F Overholt,et al.  Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus. , 1996, Gastroenterology.

[16]  K Svanberg,et al.  Detection of adenocarcinoma in Barrett's oesophagus by means of laser induced fluorescence. , 1996, Gut.

[17]  H Messmann,et al.  Endoscopic fluorescence detection of dysplasia in patients with Barrett's esophagus, ulcerative colitis, or adenomatous polyps after 5-aminolevulinic acid-induced protoporphyrin IX sensitization. , 1999, Gastrointestinal endoscopy.

[18]  J. Mayberry,et al.  Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus , 1988, The British journal of surgery.

[19]  A Gorchein,et al.  Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study. , 1995, Gut.